A high quality enzyme immunoassay for the quantification of human myeloperoxidase in serum or plasma.
Read the Directions for Use
If controls are needed please contact Mercodia for further information
Immunoassay for quantitative determination of human MPO (myeloperoxidase) in serum or plasma.
Format: 1 x 96 wells
Samples: Serum, plasma
Sample volume: 25 μL
Assay range: 3,5 - 200 μg/L
Detection limit: ≤ 3 μg/L
Incubation: (min) 60+60+15
The detection limit is ≤ 3 μg/L as determined with the
methodology described in ISO11843-Part 4.
Recovery upon addition is 84 - 98 % (89 %).
Recovery upon dilution is 94 - 114 % (101 %).
Each sample was analyzed in 4 replicates on 33 different
|Sample||Mean Value||Coefficient of variation|
|(μg/L)||within assay %||between assay %||total assay %|
Serum and EDTA plasma can be used.
Sample type will affect the level of MPO measured in a sample. The highest levels will be obtained with serum samples. The level of MPO increases continuously from blood collection to centrifugation and serum isolation, due to disintegration of MPO containing cells. To obtain comparable values from each sample it is therefore of great importance to treat all samples the same, i.e. let them clot an equal amount of time before centrifugation.
EDTA plasma samples will give lower levels of MPO, but is preferable if the aim is to measure circulating levels of MPO. The EDTA has a strong chelating effect and prevents degranulation of blood cells.
Grossly lipemic, icteric or haemolyzed samples do not interfere in the assay.
Mercodia MPO ELISA is a solid phase two-site enzyme immunoassay based on the sandwich technique, in which two
monoclonal antibodies are directed against separate antigenic determinants on the MPO molecule. MPO in the sample reacts
with anti-MPO antibodies bound to microtitration wells and peroxidase-conjugated anti-MPO antibodies in the solution.
Summary of protocol
The following cross-reactions have been tested:
|TPO||< 0.01 %|
|CRP||< 0.01 %|
|a 1-antitrypsin||< 0.01 %|
Russell, M. et al. Determining myeloperoxidase activity and protein concentration in a single assay: Utility in biomarker and therapeutic studies. J. Immunol. Methods 449, 76–79 (2017).
van der Zwan, L, P, Scheffer, P (2011)
Systemic inflammation is linked to low arginine and high ADMA plasma levels resulting in an unfavorable NOS substrate-to-inhibitor ratio - the Hoorn Study
Metzig, A, M, Schwarzenberg, S (2011)
Postprandial Endothelial Function, Inflammation, and Oxidative Stress in Obese Children and Adolescents
Lerman, R, H, Desai, A (2014)
A Phytochemical-rich Multivitamin-multimineral Supplement Is Bioavailable and Reduces Serum Oxidized Low-density Lipoprotein, Myeloperoxidase, and Plasminogen Activator Inhibitor-1 in a Four-week Pilot trial of Healthy Individuals